Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?

被引：4

作者：

Duma, Narjust ^{[1
]}

Gast, Kelly C. ^{[2
]}

Choong, Grace M. ^{[2
]}

Leon-Ferre, Roberto A. ^{[1
]}

O'Sullivan, Ciara C. ^{[1
]}

机构：

[1] Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA

[2] Mayo Clin, Dept Internal Med, Rochester, MN 55905 USA

来源：

CURRENT ONCOLOGY REPORTS | 2018年 / 20卷 / 08期

关键词：

Poly(ADP-ribose) polymerases; PARP inhibitors; Triple-negative breast cancer; BRCA1/2; mutations; BRCAness; BRCA MUTATION CARRIERS; PHASE-I TRIAL; POLY(ADP-RIBOSE) POLYMERASE; DNA-DAMAGE; OVARIAN-CARCINOMA; DOSE-ESCALATION; MUTANT-CELLS; OLAPARIB; RESISTANCE; REPAIR;

D O I：

10.1007/s11912-018-0709-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To provide an overview of the clinical development of poly(ADP-ribose) polymerase inhibitors (PARPi) in breast cancer to date and to review existing challenges and future research directions. We summarize the clinical development of PARPi in breast cancer from bench to bedside, and discuss the results of recent phase 3 trials in patients with metastatic breast cancer (MBC) and germline mutations in BRCA1/2 (gBRCAm). We will also provide an update regarding mechanisms of action and resistance to PARPi, and review clinical trials of PARPi as monotherapy or in combination regimens. PARPi are a novel treatment approach in persons with gBRCA1/2m-associated MBC. Going forward, the clinical applicability of these compounds outside the gBRCAm setting will be studied in greater detail. The identification of accurate predictive biomarkers of response is a research priority.

引用

页数：12

共 72 条

[1] Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer [J].

Abkevich, V. ;

Timms, K. M. ;

Hennessy, B. T. ;

Potter, J. ;

Carey, M. S. ;

Meyer, L. A. ;

Smith-McCune, K. ;

Broaddus, R. ;

Lu, K. H. ;

Chen, J. ;

Tran, T. V. ;

Williams, D. ;

Iliev, D. ;

Jammulapati, S. ;

FitzGerald, L. M. ;

Krivak, T. ;

DeLoia, J. A. ;

Gutin, A. ;

Mills, G. B. ;

Lanchbury, J. S. .

BRITISH JOURNAL OF CANCER, 2012, 107 (10) :1776-1782

[2] Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition [J].

Aguilar-Quesada, Rocio ;

Munoz-Gamez, Jose Antonio ;

Martin-Oliva, David ;

Peralta, Andreina ;

Valenzuela, Ma Teresa ;

Matinez-Romero, Ruben ;

Quiles-Perez, Rosa ;

Menissier-de Murcia, Josiane ;

de Murcia, Gilbert ;

Ruiz de Almodovar, Mariano ;

Javier Oliver, F. .

BMC MOLECULAR BIOLOGY, 2007, 8

[3] Defective Repair of Oxidative DNA Damage in Triple-Negative Breast Cancer Confers Sensitivity to Inhibition of Poly(ADP-Ribose) Polymerase [J].

Alli, Elizabeth ;

Sharma, Vandana B. ;

Sunderesakumar, Preethi ;

Ford, James M. .

CANCER RESEARCH, 2009, 69 (08) :3589-3596

[4] Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study [J].

Ang, Joo Ern ;

Gourley, Charlie ;

Powell, C. Bethan ;

High, Hilda ;

Shapira-Frommer, Ronnie ;

Castonguay, Vincent ;

De Greve, Jacques ;

Atkinson, Tina ;

Yap, Timothy A. ;

Sandhu, Shahneen ;

Banerjee, Susana ;

Chen, Lee-May ;

Friedlander, Michael L. ;

Kaufman, Bella ;

Oza, Amit M. ;

Matulonis, Ursula ;

Barber, Louise J. ;

Kozarewa, Iwanka ;

Fenwick, Kerry ;

Assiotis, Ioannis ;

Campbell, James ;

Chen, Lina ;

de Bono, Johann S. ;

Gore, Martin E. ;

Lord, Christopher J. ;

Ashworth, Alan ;

Kaye, Stan B. .

CLINICAL CANCER RESEARCH, 2013, 19 (19) :5485-5493

[5] Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors [J].

Balmana, J. ;

Tung, N. M. ;

Isakoff, S. J. ;

Grana, B. ;

Ryan, P. D. ;

Saura, C. ;

Lowe, E. S. ;

Frewer, P. ;

Winer, E. ;

Baselga, J. ;

Garber, J. E. .

ANNALS OF ONCOLOGY, 2014, 25 (08) :1656-1663

[6] Stumbling Blocks on the Path to Personalized Medicine in Breast Cancer: The Case of PARP Inhibitors for BRCA1/2-Associated Cancers [J].

Balmana, Judith ;

Domchek, Susan M. ;

Tutt, Andrew ;

Garber, Judy E. .

CANCER DISCOVERY, 2011, 1 (01) :29-34

[7] Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor [J].

Barber, Louise J. ;

Sandhu, Shahneen ;

Chen, Lina ;

Campbell, James ;

Kozarewa, Iwanka ;

Fenwick, Kerry ;

Assiotis, Ioannis ;

Rodrigues, Daniel Nava ;

Reis Filho, Jorge S. ;

Moreno, Victor ;

Mateo, Joaquin ;

Molife, L. Rhoda ;

De Bono, Johann ;

Kaye, Stan ;

Lord, Christopher J. ;

Ashworth, Alan .

JOURNAL OF PATHOLOGY, 2013, 229 (03) :422-429

[8] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[9] DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis [J].

Bernstein, C ;

Bernstein, H ;

Payne, CM ;

Garewal, H .

MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2002, 511 (02) :145-178

[10] OPINION γH2AX and cancer [J].

Bonner, William M. ;

Redon, Christophe E. ;

Dickey, Jennifer S. ;

Nakamura, Asako J. ;

Sedelnikova, Olga A. ;

Solier, Stephanie ;

Pommier, Yves .

NATURE REVIEWS CANCER, 2008, 8 (12) :957-967

← 1 2 3 4 5 6 7 8 →